Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions

Inclusion Criteria: * Patient was ≥ 18 years old. * Eligible for percutaneous coronary intervention. * Documented stable angina pectoris. * LVEF of greater than 25%. * Acceptable candidate for coronary artery bypass grafting. * Target lesion segment is located within a single native coronary vessel. * Target lesion was de novo. * RVD was greater than 2.25 mm and less than 4.0 mm .and patient and/or lesion fulfilled protocol defined subgroups. * Cumulative target lesion length was greater than 10 mm and less than 46mm assessed after pre-dilatation with standard balloon or cutting balloon angioplasty, including adjacent areas of dissection that were covered. * Target lesion diameter stenosis less than 50% before pre-dilatation . * Vessel and lesion morphology such that the lesion was treated only with study stent(s); no planned use of commercial stents. Exclusion Criteria: * Known hypersensitivity to paclitaxel. * Any previous or planned treatment with a non-study anti-restenotic drug-coated or drug-eluting coronary stent. * Planned use of both the study stent and a non-study stent in the treatment of the target vessel. * Previous or planned treatment with intravascular brachytherapy in the target vessel. * Recent MI. * CK-MB greater than 2x the local laboratory's upper limit of normal. * Cerebrovascular accident within 6 months of randomization. * Planned CABG ≤ 9 months post index procedure. * Acute or chronic renal dysfunction. * Leukopenia. * Thrombocytopenia or thrombocytosis. * Active peptic ulcer or active gastrointestinal bleeding, or previously active within 6 months. * Known allergy to stainless steel. * Any prior true anaphylactic reaction to contrast agents. * Contraindication to ASA or to both clopidogrel and ticlopidine. * Patient was on warfarin or it was anticipated that treatment with warfarin would have been required during any period within 6 months post the index procedure. * Patient was or had been treated with chemotherapeutic agents within 12 months of the index procedure. * Anticipated treatment with paclitaxel, oral rapamycin or colchicine during any period in the 9 months post index procedure. * Male or female with known intention to procreate within 3 months post index procedure. * Co-morbid condition(s) that could limit the patient's ability to participate in the study, limit compliance with follow-up requirements or impact the scientific integrity of the study. * Planned surgical procedure requiring withdrawal of any anti-platelet therapy within 6 months post index procedure. * Currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study. * Unprotected left main coronary artery disease. * Target lesion was ostial in location. * Target lesion and/or target vessel proximal to the target lesion was moderately or severely calcified. * Target lesion was located within or distal to a \> 60° bend in the vessel. * Side branch of the target lesion included ostial narrowing ≥ 50% DS and was ≥ 2.0 mm diameter. * Target lesion was totally occluded. * Angiographic presence of probable or definite thrombus.